
Manesh Patel, MD, kicks off his first podcast by discussing HFpEF findings in EMPEROR-Preserved, the GUIDE-HF trial and more with his Duke colleague.

Manesh Patel, MD, kicks off his first podcast by discussing HFpEF findings in EMPEROR-Preserved, the GUIDE-HF trial and more with his Duke colleague.

FMT treatment was less effective for primary C difficile infections.

The regulatory setback is regarding a manufacturing facility concern not associated with the investigative drug, according to the company.

Students who received eyeglasses through a school-based vision program achieved better reading scores, but sustained impact not observed after 2 years.

Incidence of myopia was 7.9% higher in the exposure group, compared to the non-exposure group from grade 2 to grade 3.

The FODMAP diet is considered a preferable option for patients with irritable bowel syndrome.

The approval of ranibizumab-nuna marks the first ophthalmology biosimilar to become FDA approved in the United States.

An Australian study used data consistent with international literature on the subject of de-labeling penicillin for low-risk allergy patients.

A total of 269 participants were considered potentially overtreated, while 109 participants were appropriately on target, and 56 participants potentially undertreated.

Though previous studies have measured different levels of physical activity, few before this have considered the interrelationship involving body mass index and childhood asthma control.

The VRBPAC voted 16-2 against the booster dose because of unclear evidence regarding the need.

The potential number of adults projected to be newly eligible for treatment had a range from 643,161 (LVEF, 41% - 50%) to 1,838,756 (LVEF, 41% - 60%).

The US Pain Foundation starts off September strong for Pain Awareness Month by releasing a touching video that gets personal about chronic pain.

The machine learning model outperformed a comparison logistic regression model in identifying high-risk patients for HBV.

As predicted, previous asthma during early childhood was a strong risk factor for asthma in young adulthood.

Most of Europe lacks an active and coordinated surveillance plan in place for monitoring hospital-acquired CDI.

Investigators report that few medical schools in Europe consider allergology to be an important area of study, resulting in a lack of knowledge regarding certain allergy practices.

HCPLive Crisis Point takes an in-depth look at the obesity crisis, beginning with the process of medical diagnosis and who is impacted the most by the disease.

Patients with chronic pain may benefit from rotation to buprenorphine.

Though well-tolerated and highly efficacious, the biologic was linked several adverse events in pediatric patients with atopic dermatitis including facial erythema and herpes simplex virus.

Hospitals that use the 3-dose vaccine would spend approximately 37% more on prophylaxis for hepatitis B.

In this episode of Derm Discussions, vitiligo expert John Harris, MD, PhD, discusses new tactics and therapeutic options in treating inflammatory skin disorders like vitiligo, alopecia areata, and atopic dermatitis.

The evidence regarding patients with entecavir-treated chronic hepatitis B without maintaining virological response is limited and uncertain.

The TMIOA Medical Director and Principal Investigator discusses the idea behind hosting a mixed in-person and virtual conference for this year's Heart in Diabetes.

Though the severity of the COVID-19 virus did not differ in participants with different dermatological conditions, their conditions were affected in alternate ways.

Voxelotor has the potential to decrease long-term problems in pediatric sickle cell disease.

Dr. Papadopoulos reports on new phase 3 data from the LIBERTY VOYAGE ASTHMA study on patients aged 6-11 with moderate-to-severe asthma.

Dr. Ezhkova and fellow investigators found that low UV exposure prompted an increase in pigmentation production through melanocytes in the body.

The new PDUFA date for Nefecon will be December 15, 2021.

An expert considers the buildup of cardiovascular and cardiometabolic innovation, and the role of regulatory delays in it.